Dermatofibrosarcoma protuberans

Summary

Dermatofibrosarcoma protuberans (MONDO:0011934) is a disease with 3 cohort genes and 12 clinical trials. Molecularly, COL1A1::PDGFB Fusion confers sensitivity to Imatinib in Dermatofibrosarcoma Protuberans (CIViC Level A); 6 further subtype–drug associations are mapped below. Top therapeutic interventions include ifosfamide, imatinib, and vismodegib.

At a glance

• Prevalence: 1-5 / 10 000 (Europe) [Orphanet-validated]
• Cohort genes: 3
• ClinVar variants: 4
• Phenotypes (HPO): 8
• Clinical trials: 12
• Precision-medicine evidence (CIViC): 7 subtype–drug associations

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Point prevalence	1-5 / 10 000	10	Europe	Validated

Signs & symptoms

Clinical features (HPO)

8 HPO clinical features (Orphanet curated; top 8 by frequency):

HPO ID	Term	Frequency
HP:0001072	Thickened skin	Very frequent (80-99%)
HP:0001482	Subcutaneous nodule	Very frequent (80-99%)
HP:0008069	Neoplasm of the skin	Very frequent (80-99%)
HP:0010783	Erythema	Very frequent (80-99%)
HP:0100244	Fibrosarcoma	Very frequent (80-99%)
HP:0200042	Skin ulcer	Frequent (30-79%)
HP:0012531	Pain	Occasional (5-29%)
HP:0002716	Lymphadenopathy	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	dermatofibrosarcoma protuberans
Mondo ID	MONDO:0011934
MeSH	D018223
OMIM	607907
Orphanet	31112
DOID	DOID:3507
ICD-11	1579898301
NCIT	C4683
SNOMED CT	276799004
UMLS	C3693482
MedGen	811326
GARD	0009569
MedDRA	10057070
Is cancer (heuristic)	no

Also known as: dermatofibrosarcoma · dermatofibrosarcoma protuberans · DFSP · familial dermatofibrosarcoma protuberans (subtype) · metastatic dermatofibrosarcoma protuberans (subtype)

Data availability: 4 ClinVar variants · 10 cell lines.

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › integumentary system cancer › dermatofibrosarcoma protuberans

Related subtypes (6): bartholin gland carcinoma, skin cancer, nipple carcinoma, breast adenocarcinoma, atypical lobular breast hyperplasia, breast diffuse large B-cell lymphoma

Subtypes (1): pigmented dermatofibrosarcoma protuberans

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

4 retrieved; paginated sample, class counts are floors:

2 benign/likely benign, 1 pathogenic, 1 benign

ClinVar	Variant (HGVS)	Gene	Classification	Review
12599	PDGFB, PDGFB/COL1A1 FUSION	PDGFB	Pathogenic	no assertion criteria provided
522278	NM_002608.4(PDGFB):c.670C>T (p.Arg224Trp)	PDGFB	Benign/Likely benign	criteria provided, multiple submitters, no conflicts
522279	NM_002608.4(PDGFB):c.635C>T (p.Thr212Met)	PDGFB	Benign/Likely benign	criteria provided, multiple submitters, no conflicts
522280	NM_002608.4(PDGFB):c.160+15C>A	PDGFB	Benign	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 19 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
CDKN2A	Orphanet:1333	Familial pancreatic carcinoma
CDKN2A	Orphanet:1501	Adrenocortical carcinoma
CDKN2A	Orphanet:252206	Melanoma and neural system tumor syndrome
CDKN2A	Orphanet:404560	Familial atypical multiple mole melanoma syndrome
CDKN2A	Orphanet:524	Li-Fraumeni syndrome
CDKN2A	Orphanet:585909	B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)
CDKN2A	Orphanet:618	Familial melanoma
CDKN2A	Orphanet:99861	Precursor T-cell acute lymphoblastic leukemia
PDGFRB	Orphanet:168950	Myeloid/lymphoid neoplasm associated with PDGFRB rearrangement
PDGFRB	Orphanet:1980	Bilateral striopallidodentate calcinosis
PDGFRB	Orphanet:2591	Infantile myofibromatosis
PDGFRB	Orphanet:314950	Primary hypereosinophilic syndrome
PDGFRB	Orphanet:363665	Acroosteolysis-keloid-like lesions-premature aging syndrome
PDGFRB	Orphanet:477831	Kosaki overgrowth syndrome
PDGFRB	Orphanet:86830	Chronic myeloproliferative disease, unclassifiable
PDGFB	Orphanet:1980	Bilateral striopallidodentate calcinosis
PDGFB	Orphanet:2495	Meningioma
PDGFB	Orphanet:263662	Familial multiple meningioma
PDGFB	Orphanet:31112	Dermatofibrosarcoma protuberans

Cohort genes → proteins

3 cohort genes, 3 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	2
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
CDKN2A	HGNC:1787	ENSG00000147889	P42771	Cyclin-dependent kinase inhibitor 2A	civic_evidence
PDGFRB	HGNC:8804	ENSG00000113721	P09619	Platelet-derived growth factor receptor beta	civic_evidence
PDGFB	HGNC:8800	ENSG00000100311	P01127	Platelet-derived growth factor subunit B	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
CDKN2A	Cyclin-dependent kinase inhibitor 2A	Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6.
PDGFRB	Platelet-derived growth factor receptor beta	Tyrosine-protein kinase that acts as a cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, surviv…
PDGFB	Platelet-derived growth factor subunit B	Growth factor that plays an essential role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis.

Protein-family classification

Druggable: 1 · Difficult: 1 · Unknown: 1 · Druggable fraction: 0.33

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	1	9.2×	0.246
Scaffold/PPI	1	5.8×	0.246
Other/Unknown	1	0.6×	0.914

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
CDKN2A	Scaffold/PPI	no		Ankyrin_rpt-contain_sf, Ank_Repeat/CDKN_Inhibitor, Tumor_suppres_ARF
PDGFRB	Kinase	yes	2.7.10.1	Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom, Tyr_kinase_rcpt_3_CS
PDGFB	Other/Unknown	no		PDGF/VEGF_dom, PDGF_N, PD_growth_factor_CS

Expression context

Cohort genes with no expression data: 0.

3 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	3
unknown	0

Top tissues across cohort

Tissue	Cohort genes
cervix squamous epithelium	1
parotid gland	1
pituitary gland	1
endocervix	1
right coronary artery	1
stromal cell of endometrium	1
apex of heart	1
olfactory bulb	1
type B pancreatic cell	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
CDKN2A	220	ubiquitous	marker	parotid gland, cervix squamous epithelium, pituitary gland
PDGFRB	270	ubiquitous	marker	stromal cell of endometrium, right coronary artery, endocervix
PDGFB	259	ubiquitous	marker	olfactory bulb, type B pancreatic cell, apex of heart

Protein interactions among cohort

Intra-cohort edges: 1.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
CDKN2A	9,311
PDGFRB	5,111
PDGFB	2,424

Intra-cohort edges

A	B	Sources
PDGFB	PDGFRB	biogrid_interaction, intact, string_interaction

Structural data

PDB: 3 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
PDGFRB	P09619	8
PDGFB	P01127	6
CDKN2A	P42771	5

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 66. Enrichment computed across 3 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Downstream signal transduction	2	253.8×	0.001	PDGFB, PDGFRB
Signaling by PDGF	2	169.2×	0.001	PDGFB, PDGFRB
Evasion of Oncogene Induced Senescence Due to p14ARF Defects	1	3806.7×	0.003	CDKN2A
Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects	1	3806.7×	0.003	CDKN2A
Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4	1	1903.3×	0.003	CDKN2A
Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4	1	1903.3×	0.003	CDKN2A
Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function	1	1903.3×	0.003	CDKN2A
Diseases of Cellular Senescence	1	1268.9×	0.003	CDKN2A
Evasion of Oncogene Induced Senescence Due to p16INK4A Defects	1	1268.9×	0.003	CDKN2A
Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6	1	1268.9×	0.003	CDKN2A
Evasion of Oxidative Stress Induced Senescence Due to p16INK4A Defects	1	1268.9×	0.003	CDKN2A
Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6	1	1268.9×	0.003	CDKN2A
Diseases of cellular response to stress	1	1268.9×	0.003	CDKN2A
Constitutive Signaling by Aberrant PI3K in Cancer	2	84.6×	0.003	PDGFB, PDGFRB
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	2	64.5×	0.003	PDGFB, PDGFRB
PIP3 activates AKT signaling	2	44.5×	0.003	PDGFB, PDGFRB
RAF/MAP kinase cascade	2	40.7×	0.003	PDGFB, PDGFRB
RUNX3 regulates p14-ARF	1	380.7×	0.010	CDKN2A
Apoptotic factor-mediated response	1	292.8×	0.012	CDKN2A
Stabilization of p53	1	253.8×	0.012	CDKN2A
Defective Intrinsic Pathway for Apoptosis	1	253.8×	0.012	CDKN2A
p53-Dependent G1 DNA Damage Response	1	237.9×	0.012	CDKN2A
p53-Dependent G1/S DNA damage checkpoint	1	237.9×	0.012	CDKN2A
G1/S DNA Damage Checkpoints	1	223.9×	0.012	CDKN2A
Diseases of programmed cell death	1	211.5×	0.012	CDKN2A
SUMOylation of transcription factors	1	190.3×	0.013	CDKN2A
Regulation of MITF-M-dependent genes involved in cell cycle and proliferation	1	190.3×	0.013	CDKN2A
Regulation of TP53 Expression and Degradation	1	173.0×	0.014	CDKN2A
G1 Phase	1	131.3×	0.017	CDKN2A
Oncogene Induced Senescence	1	112.0×	0.019	CDKN2A

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway	2	3744.9×	8e-06	PDGFB, PDGFRB
smooth muscle adaptation	2	2808.7×	8e-06	PDGFB, PDGFRB
positive regulation of DNA biosynthetic process	2	749.0×	8e-05	PDGFB, PDGFRB
positive regulation of smooth muscle cell migration	2	660.9×	8e-05	PDGFB, PDGFRB
positive regulation of calcium ion import	2	624.1×	8e-05	PDGFB, PDGFRB
positive regulation of chemotaxis	2	561.7×	8e-05	PDGFB, PDGFRB
positive regulation of MAP kinase activity	2	432.1×	1e-04	PDGFB, PDGFRB
platelet-derived growth factor receptor signaling pathway	2	374.5×	1e-04	PDGFB, PDGFRB
positive regulation of mitotic nuclear division	2	362.4×	1e-04	PDGFB, PDGFRB
positive regulation of reactive oxygen species metabolic process	2	340.4×	1e-04	PDGFB, PDGFRB
peptidyl-tyrosine phosphorylation	2	280.9×	2e-04	PDGFB, PDGFRB
positive regulation of smooth muscle cell proliferation	2	220.3×	3e-04	PDGFB, PDGFRB
cell chemotaxis	2	123.5×	8e-04	PDGFB, PDGFRB
cell migration involved in coronary angiogenesis	1	5617.3×	0.001	PDGFRB
metanephric glomerular mesangial cell development	1	5617.3×	0.001	PDGFB
metanephric glomerular mesangial cell proliferation involved in metanephros development	1	5617.3×	0.001	PDGFRB
positive regulation of vascular associated smooth muscle cell dedifferentiation	1	5617.3×	0.001	PDGFB
positive regulation of metanephric mesenchymal cell migration	1	5617.3×	0.001	PDGFB
negative regulation of phosphatidylinositol biosynthetic process	1	2808.7×	0.002	PDGFB
nuclear body organization	1	2808.7×	0.002	CDKN2A
cell migration involved in vasculogenesis	1	2808.7×	0.002	PDGFRB
cellular response to mycophenolic acid	1	2808.7×	0.002	PDGFB
smooth muscle cell chemotaxis	1	2808.7×	0.002	PDGFRB
positive regulation of ERK1 and ERK2 cascade	2	56.7×	0.002	PDGFB, PDGFRB
positive regulation of glomerular filtration	1	1872.4×	0.002	PDGFB
positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway	1	1872.4×	0.002	PDGFRB
apoptotic process involved in mammary gland involution	1	1872.4×	0.002	CDKN2A
metanephric glomerular capillary formation	1	1872.4×	0.002	PDGFRB
positive regulation of macrophage apoptotic process	1	1872.4×	0.002	CDKN2A
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	2	52.2×	0.002	PDGFB, PDGFRB

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Ifosfamide	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Pazopanib.

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 2

Druggability breadth: 3 of 3 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
PDGFRB	PONATINIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
PDGFRB	102	4
CDKN2A	0	0
PDGFB	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
PONATINIB	4	PDGFRB
FEDRATINIB	4	PDGFRB
TIVOZANIB	4	PDGFRB
LENVATINIB	4	PDGFRB
AXITINIB	4	PDGFRB
SORAFENIB	4	PDGFRB
SUNITINIB MALATE	4	PDGFRB
REGORAFENIB	4	PDGFRB
PACRITINIB	4	PDGFRB
VANDETANIB	4	PDGFRB
NILOTINIB	4	PDGFRB
BOSUTINIB	4	PDGFRB
NINTEDANIB ESYLATE	4	PDGFRB
GILTERITINIB	4	PDGFRB
TOVORAFENIB	4	PDGFRB
PEXIDARTINIB	4	PDGFRB
PAZOPANIB	4	PDGFRB
NINTEDANIB	4	PDGFRB
SUNITINIB	4	PDGFRB
DASATINIB	4	PDGFRB
ERLOTINIB	4	PDGFRB
LAPATINIB	4	PDGFRB
QUIZARTINIB	4	PDGFRB
MIDOSTAURIN	4	PDGFRB
IMATINIB	4	PDGFRB
VATALANIB	3	PDGFRB
FAMITINIB	3	PDGFRB
MASITINIB	3	PDGFRB
CRENOLANIB	3	PDGFRB
SARACATINIB	3	PDGFRB

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
PDGFRB	1,237	Binding:1213, Functional:16, ADMET:8
PDGFB	3	Binding:3
CDKN2A	2	Binding:2

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
PDGFRB	2.7.10.1	receptor protein-tyrosine kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
PDGFRB	1,237

Pharmacogenomics

Cohort genes with a PharmGKB record: 3; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

28 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
PONATINIB	4	PDGFRB
FEDRATINIB	4	PDGFRB
TIVOZANIB	4	PDGFRB
LENVATINIB	4	PDGFRB
AXITINIB	4	PDGFRB
SORAFENIB	4	PDGFRB
SUNITINIB MALATE	4	PDGFRB
REGORAFENIB	4	PDGFRB
PACRITINIB	4	PDGFRB
VANDETANIB	4	PDGFRB
NILOTINIB	4	PDGFRB
BOSUTINIB	4	PDGFRB
NINTEDANIB ESYLATE	4	PDGFRB
GILTERITINIB	4	PDGFRB
TOVORAFENIB	4	PDGFRB
PEXIDARTINIB	4	PDGFRB
PAZOPANIB	4	PDGFRB
NINTEDANIB	4	PDGFRB
SUNITINIB	4	PDGFRB
DASATINIB	4	PDGFRB
ERLOTINIB	4	PDGFRB
LAPATINIB	4	PDGFRB
QUIZARTINIB	4	PDGFRB
MIDOSTAURIN	4	PDGFRB
VATALANIB	3	PDGFRB
FAMITINIB	3	PDGFRB
MASITINIB	3	PDGFRB
CRENOLANIB	3	PDGFRB

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	PDGFRB
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	2	CDKN2A, PDGFB

Undrugged target profiles

2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
PDGFB	3	PDGFRB
CDKN2A	2	—

Clinical trials & evidence

Clinical trials

Clinical trials: 12.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	4
PHASE1/PHASE2	3
PHASE1	2
Not specified	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00346164	PHASE3	COMPLETED	Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
NCT00084630	PHASE2	COMPLETED	Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans
NCT00122473	PHASE1/PHASE2	COMPLETED	Imatinib in Dermatofibrosarcoma Protuberans (DFSP)
NCT00171912	PHASE2	COMPLETED	Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
NCT00243191	PHASE2	COMPLETED	Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans
NCT00659360	PHASE2	COMPLETED	AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
NCT01154452	PHASE1/PHASE2	COMPLETED	Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
NCT01962103	PHASE1/PHASE2	COMPLETED	Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
NCT06610071	PHASE1	NOT_YET_RECRUITING	NIFR Image-guided Surgery for Malignant Soft Tissue Tumor With Low-dose SWIG Technique
NCT00720174	PHASE1	COMPLETED	Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
NCT02310503	Not specified	COMPLETED	Spanish Registry of Mohs Surgery
NCT03381846	Not specified	COMPLETED	Treatment of Dermatofibrosarcoma Protuberans in Patients 10 Years and Younger

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
IFOSFAMIDE	4	1
IMATINIB	4	1
VISMODEGIB	4	1
SARACATINIB	3	1
CIXUTUMUMAB	2	1
CHEMBL4438584	0	1

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 7 predictive associations from 11 curated evidence items; also 6 diagnostic, 1 oncogenic.

Molecular subtype	Therapy	Effect	Level	CIViC
COL1A1::PDGFB Fusion	Imatinib	Sensitivity/Response	CIViC A	EID11271
COL1A1::PDGFB Fusion	Imatinib Mesylate	Sensitivity/Response	CIViC B	EID10332 +3
PDGFB Rearrangement	Imatinib Mesylate	Sensitivity/Response	CIViC C	EID10312 +1
COL1A1::PDGFB Fusion	Sunitinib	Sensitivity/Response	CIViC C	EID7991
PDGFB Rearrangement	Sorafenib Tosylate	Sensitivity/Response	CIViC C	EID10333
PDGFRB Overexpression	Sunitinib	Sensitivity/Response	CIViC C	EID7992
CDKN2A Loss	Palbociclib	Sensitivity/Response	CIViC D	EID1881